

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Boill Healthcare Holdings Limited

保集健康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1246)

PROFIT WARNING

This announcement is made by Boill Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the Board’s preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 September 2022 (the “**Period**”), the Group is expected to record a consolidated net loss of not less than approximately HK\$128 million for the Period, as compared with the consolidated net loss of approximately HK\$27 million for the six months ended 30 September 2021. Such expected substantial consolidated net loss for the Period was mainly due to the following factors:

- (i) the expected fair value loss on investment properties and impairment loss on property, plant and equipment for the Period due to the adverse impact caused by the outbreak of COVID-19 pandemic and weakened demand of potential home-buying customers due to deterioration of their overall financial condition brought by the uncertain global macro-economic environment; and
- (ii) the decrease in revenue and gross profit recognised during the Period as a result of delay of properties delivery during the COVID-19 lockdown in certain cities in Mainland China.

The Company is still in the process of finalising the interim results of the Group for the Period. The information contained in this announcement is only based on preliminary assessment made by the Board with reference to the unaudited consolidated management accounts of the Group for the Period and other information currently available to the Board, which have not been audited or reviewed by the Company’s auditors nor reviewed by the audit committee of the Company. The unaudited interim results of the Group for the Period may be subject to adjustments, if any, upon further review.

Shareholders and potential investors are advised to read carefully the interim results announcement of the Group for the Period for further details, which is expected to be published on or about 30 November 2022.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Boill Healthcare Holdings Limited
Qiu Dongfang
Executive Director and Chairman

Hong Kong, 17 November 2022

As at the date of this announcement, the Board comprises (i) three executive Directors, namely Mr. Qiu Dongfang, Mr. Zhang Sheng Hai and Ms. Yu Yixing; (ii) two non-executive Directors, namely Mr. Chui Kwong Kau and Mr. Qiu Bin; and (iii) three independent non-executive Directors, namely Mr. Chan Chi Keung, Billy, Mr. Wang Zhe and Mr. Yi Baxian.

In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.